HomeMYD • FRA
Myriad Genetics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 195.90M | -3.12% |
Operating expense | 163.20M | -1.39% |
Net income | -100.00K | 99.62% |
Net profit margin | -0.05 | 99.61% |
Earnings per share | -0.03 | -200.00% |
EBITDA | -14.60M | -19.67% |
Effective tax rate | 99.66% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 91.80M | -11.98% |
Total assets | 1.01B | -9.40% |
Total liabilities | 301.20M | -14.07% |
Total equity | 704.90M | — |
Shares outstanding | 92.18M | — |
Price to book | 0.46 | — |
Return on assets | -7.13% | — |
Return on capital | -8.51% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -100.00K | 99.62% |
Cash from operations | -16.30M | 12.37% |
Cash from investing | -8.30M | -16.90% |
Cash from financing | 13.60M | 254.55% |
Net change in cash | -10.90M | 69.12% |
Free cash flow | -13.93M | 28.04% |
Previous close
€3.54
Day range
€3.42 - €3.42
Year range
€3.40 - €25.80
Market cap
360.41M USD
Avg Volume
60.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
Founded
1991
Headquarters
Website
Employees
2,700
